Synlogic (SYBX) Competitors $1.42 +0.05 (+3.52%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SYBX vs. VTGN, RPTX, VOR, VHAQ, BCAB, CUE, SLS, OSTX, INCR, and DBVTShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Vistagen Therapeutics (VTGN), Repare Therapeutics (RPTX), Vor Biopharma (VOR), Viveon Health Acquisition (VHAQ), BioAtla (BCAB), Cue Biopharma (CUE), SELLAS Life Sciences Group (SLS), OS Therapies (OSTX), InterCure (INCR), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Vistagen Therapeutics Repare Therapeutics Vor Biopharma Viveon Health Acquisition BioAtla Cue Biopharma SELLAS Life Sciences Group OS Therapies InterCure DBV Technologies Vistagen Therapeutics (NASDAQ:VTGN) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations. Which has more risk & volatility, VTGN or SYBX? Vistagen Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Does the MarketBeat Community favor VTGN or SYBX? Synlogic received 49 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. However, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 69.54% of users gave Synlogic an outperform vote. CompanyUnderperformOutperformVistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% SynlogicOutperform Votes33169.54% Underperform Votes14530.46% Do institutionals and insiders believe in VTGN or SYBX? 78.4% of Vistagen Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 1.3% of Vistagen Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is VTGN or SYBX more profitable? Synlogic has a net margin of -2,284.65% compared to Vistagen Therapeutics' net margin of -4,521.71%. Vistagen Therapeutics' return on equity of -36.35% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets Vistagen Therapeutics-4,521.71% -36.35% -33.62% Synlogic -2,284.65%-207.84%-114.81% Which has better earnings & valuation, VTGN or SYBX? Vistagen Therapeutics has higher earnings, but lower revenue than Synlogic. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistagen Therapeutics$876K79.46-$29.36M-$1.24-2.02Synlogic$3.37M4.93-$57.28M-$4.16-0.34 Do analysts recommend VTGN or SYBX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Synlogic 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to VTGN or SYBX? In the previous week, Vistagen Therapeutics' average media sentiment score of 0.76 beat Synlogic's score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Vistagen Therapeutics Positive Synlogic Neutral SummaryVistagen Therapeutics beats Synlogic on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.54M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.3410.5990.1317.20Price / Sales4.93196.061,117.09117.05Price / CashN/A57.1643.1037.85Price / Book0.315.094.784.78Net Income-$57.28M$151.83M$120.31M$225.60M7 Day Performance-5.33%-2.14%-1.92%-1.23%1 Month Performance-0.70%-4.56%13.65%0.46%1 Year Performance-60.99%8.87%28.34%15.24% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogicN/A$1.42+3.5%N/A-53.1%$17.54M$3.37M-0.346VTGNVistagen Therapeutics0.9756 of 5 stars$2.49+2.5%N/A-51.0%$69.32M$1.06M-1.9640Positive NewsRPTXRepare Therapeutics3.2522 of 5 stars$1.61-9.0%$7.00+334.8%-79.8%$68.44M$51.13M-0.89180High Trading VolumeVORVor Biopharma2.7374 of 5 stars$0.99+0.4%$11.36+1,041.5%-59.7%$68.32MN/A-0.60140Positive NewsVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002BCABBioAtla2.4604 of 5 stars$1.37-5.5%$6.00+338.0%-69.2%$66.23M$11M-0.8560News CoverageGap DownCUECue Biopharma4.6871 of 5 stars$1.04+10.6%$5.00+380.8%-64.2%$65.88M$9.53M-1.1660News CoveragePositive NewsSLSSELLAS Life Sciences Group0.0104 of 5 stars$0.93+7.1%N/A-22.8%$65.74M$1M-1.3916OSTXOS TherapiesN/A$3.09+2.3%$8.00+158.9%N/A$65.63MN/A0.00N/AGap UpINCRInterCure0.1051 of 5 stars$1.43+8.2%N/A+14.6%$64.94M$272.67M0.00350News CoverageGap UpDBVTDBV Technologies3.541 of 5 stars$3.13-12.3%$22.50+618.8%-65.3%$64.38M$15.73M-0.73106Gap Down Related Companies and Tools Related Companies Vistagen Therapeutics Competitors Repare Therapeutics Competitors Vor Biopharma Competitors Viveon Health Acquisition Competitors BioAtla Competitors Cue Biopharma Competitors SELLAS Life Sciences Group Competitors OS Therapies Competitors InterCure Competitors DBV Technologies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYBX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYBX Stock Alerts